Dihydroergotamine mesylate

Pricing Availability   Qty
Cat.No. 0475 - Dihydroergotamine mesylate | C33H37N5O5.CH3SO3H | CAS No. 6190-39-2
Description: Partial α agonist. Non-selective
Chemical Name: 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trione mesylate
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Partial α-adrenergic agonist. Partial D2 dopaminergic receptor agonist. Competitive 5-HT antagonist.

Compound Libraries

Dihydroergotamine mesylate is also offered as part of the Tocriscreen Plus and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 679.79
Formula C33H37N5O5.CH3SO3H
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 6190-39-2
PubChem ID 71171
InChI Key ADYPXRFPBQGGAH-UMYZUSPBSA-N
Smiles CS(=O)(O)=O.[H][C@]4([C@@]([H])3C[C@@H]([C@@](N[C@@]5(C)C(N([C@@]([H])(CC8=CC=CC=C8)C(N7[C@]([H])6CCC7)=O)[C@@]6(O)O5)=O)=O)CN4C)CC1=CNC2=C1C3=CC=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 67.97 100

Preparing Stock Solutions

The following data is based on the product molecular weight 679.79. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.47 mL 7.36 mL 14.71 mL
5 mM 0.29 mL 1.47 mL 2.94 mL
10 mM 0.15 mL 0.74 mL 1.47 mL
50 mM 0.03 mL 0.15 mL 0.29 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References

References are publications that support the biological activity of the product.

de Boer et al (1991) Carotid vascular effects of ergot. and dihydroergot. in the pig: no exclusive mediation via 5-HT1-like receptors. Br.J.Pharmacol. 104 183 PMID: 1664762

Doggrell et al (1992) Further analysis of the inhibitory effects of dihydroergotamine, cyprohept. and ketanserin on the responses of the rat aorta to 5-hydroxytryptamine. J.Auton.Pharmacol. 12 223 PMID: 1512277

Lesage et al (1998) Agonistic properties of alniditan, sumatr. and dihydroergot. on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br.J.Pharmacol. 123 1655 PMID: 9605573

Villalon et al (1992) Effects of S9977 and dihydroergot. in an animal experimental model for migraine. Pharmacol.Res. 25 125 PMID: 1635891


If you know of a relevant reference for Dihydroergotamine mesylate, please let us know.

View Related Products by Product Action

View all Non-selective Adrenergic α Receptor Agonists

Keywords: Dihydroergotamine mesylate, Dihydroergotamine mesylate supplier, 5-HT, antagonists, partial, agonists, a-adrenergic, α-adrenergic, alpha-adrenergic, dopaminergic, D2, receptors, Partial, D2-like, alpha, Non-Selective, Serotonin, 5-HT3, Receptors, 5-Hydroxytryptamine, Dopamine, α-adrenoceptors, α-adrenoceptor, alpha-adrenocep, Non-selective, Adrenergic, Alpha, 0475, Tocris Bioscience

⚠ WARNING: This product can expose you to chemicals including Dihydroergotamine mesylate, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information, go to www.P65Warnings.ca.gov

Citations for Dihydroergotamine mesylate

Citations are publications that use Tocris products.

Currently there are no citations for Dihydroergotamine mesylate. Do you know of a great paper that uses Dihydroergotamine mesylate from Tocris? Please let us know.

Reviews for Dihydroergotamine mesylate

There are currently no reviews for this product. Be the first to review Dihydroergotamine mesylate and earn rewards!

Have you used Dihydroergotamine mesylate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.